Perjeta « lancalass

My Sister Pauline, called Home Too Soon.

If tears could build a stairway and memories a lane , I would walk right up to heaven and bring you back again.

The greatest gift our parents gave us..was each other.

If I had a flower for every memory I have with you, I could forever walk in my garden.

Rest In Peace knowing how much I love you!!

All I ask is that you remember me at the alter of God.

Categories

A sundown splendid and serene,
A sister’s kiss upon your cheek,
A timeless moment when you are thanked,
You smile but cannot speak.
Such gifts are rich beyond compare,
And compensate for grief and care.
We lost a very special sister and best friend the day you were called home so suddenly and without warning..
Loved with a love beyond all telling,
Missed with a grief beyond all tears.
Goodnight and God Bless Pauline I love you and miss you so much…xxx

Re-united with her loving parents and brothers Peter and John, sister Patrica. Missed by her loving husband Peter also daughter Susan and Ebony her granddaughter,  son Anthony, and Grandsons.. Not forgetting  Brian and Granddaughter Julie.

All of you Rest In Peace!

 

Perjeta

Perjeta: Drug which prolongs lives of incurable breast cancer patients approved.

Perjeta, when used with two other drugs, can help patients lead relatively normal lives without horrifying side effects.

A drug which means incurable breast cancer patients can live a normal life will now be used across the NHS in England.

Perjeta has been approved by the National Institute for Health and Care Excellence (NICE) for routine use after five years of assessment.

Previously, it had only been available through the Cancer Drugs Fund since 2013, meaning many sufferers were not even given the option.

Used in combination with trastuzumab and a chemotherapy drug called docetaxel, Perjeta – or Pertuzumab – can give men and women with secondary breast cancer a relatively normal life.

Last year Scotland refused to make Perjeta available on the NHS as it could not>>

CREDIT: SKYNEWS

Comments are closed.